Yonsei Med J:药物洗脱支架进行CTO-PCI治疗的效果优于单纯药物治疗

2018-07-10 MedSci MedSci原创

近日,韩国的一项研究探究了药物洗脱支架(DES)进行CTO-PCI治疗的效果是否优于单纯药物治疗。研究纳入了822名慢性完全闭塞(CTO)患者,倾向评分匹配后,两组患者的基线信息基本一致(265对,n=530)。随访5年,对比两组患者主要临床结局和心脏不良事件、总死亡、心肌梗死、卒中以及血运重建的复合结局。结果显示,尽管PCI组CTO再次血运重建率更高(12.7% vs. 3.2%, P<0

近日,韩国的一项研究探究了药物洗脱支架(DES)进行CTO-PCI治疗的效果是否优于单纯药物治疗。

研究纳入了822名慢性完全闭塞(CTO)患者,倾向评分匹配后,两组患者的基线信息基本一致(265对,n=530)。随访5年,对比两组患者主要临床结局和心脏不良事件、总死亡、心肌梗死卒中以及血运重建的复合结局。

结果显示,尽管PCI组CTO再次血运重建率更高(12.7% vs. 3.2%, P<0.001),但是患者死亡率(4.3% vs. 8.6%, P=0.02)、心肌梗死率(1.8% vs. 5.5%, P=0.015)明显低于单纯药物治疗组患者。亚组分析显示,射血分数保留(LVEF>50%)、糖尿病、非LAD CTO、侧支发育良好(≥2分)、轻度CCS(≤1级)的患者其CTO-PCI的效果更佳。

综上所述,该研究结果表明,虽然PCI组CTO再次血运重建率更高,但是患者死亡率、心肌梗死率明显低于单纯药物治疗组患者。

原始出处:

Rha SW, Choi BG, et al., Five-Year Outcomes of Successful Percutaneous Coronary Intervention with Drug-Eluting Stents versus Medical Therapy for Chronic Total Occlusions. Yonsei Med J. 2018 Jul;59(5):602-610. doi: 10.3349/ymj.2018.59.5.602.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862772, encodeId=20551862e72a4, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Thu Jul 12 04:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030098, encodeId=620b203009836, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Jan 30 21:15:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998760, encodeId=61e01998e60f7, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Mon Aug 20 19:15:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310490, encodeId=5cae13104906a, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608950, encodeId=5730160895028, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 gao_jian4217
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862772, encodeId=20551862e72a4, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Thu Jul 12 04:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030098, encodeId=620b203009836, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Jan 30 21:15:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998760, encodeId=61e01998e60f7, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Mon Aug 20 19:15:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310490, encodeId=5cae13104906a, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608950, encodeId=5730160895028, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862772, encodeId=20551862e72a4, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Thu Jul 12 04:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030098, encodeId=620b203009836, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Jan 30 21:15:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998760, encodeId=61e01998e60f7, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Mon Aug 20 19:15:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310490, encodeId=5cae13104906a, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608950, encodeId=5730160895028, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1862772, encodeId=20551862e72a4, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Thu Jul 12 04:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030098, encodeId=620b203009836, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Jan 30 21:15:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998760, encodeId=61e01998e60f7, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Mon Aug 20 19:15:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310490, encodeId=5cae13104906a, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608950, encodeId=5730160895028, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862772, encodeId=20551862e72a4, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Thu Jul 12 04:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030098, encodeId=620b203009836, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Jan 30 21:15:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998760, encodeId=61e01998e60f7, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Mon Aug 20 19:15:00 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310490, encodeId=5cae13104906a, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608950, encodeId=5730160895028, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jul 12 10:15:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]

相关资讯

JACC:DES置入后短期和长期DAPT不良心脏事件及出血分析

本文是一项个体化患者数据配对与meta分析研究,主要比较了关药物洗脱支架(DES)置入后DAPT持续时间,时间段分为短期(≤6个月),长期(1年),3个月,6个月和1年。 通过检索MEDLINE, EMBASE系统和国际会议论文,并收纳了合格的4项有关药物洗脱支架(DES)置入后DAPT持续时间问题的试验(n=8180),实验主要以心源性死亡、心梗或明确/可能的支架血栓等不良心脏事件为主要结局。

JACC Cardiovasc Interv:即使用现代支架,TLR也会增加MI和死亡风险

近期研究显示,即使在药物洗脱支架(DES)的时代,非紧急靶病变再次血运重建(TLR)也会带来实质性、独立的晚期死亡风险,至少部分是由于其对随后心肌梗死(MI)风险的影响。

Eur Heart J:冠脉支架类型和双重抗血小板治疗的长度对缺血性和出血性事件的影响

不论DAPT长度如何,耐久性和可生物降解的聚合物支架与BRS的MACE比率相似。

新一代DES挑战CABG的远期死亡率优势

近日,美国学者比较并发糖尿病的多血管疾病患者使用依维莫司洗脱支架行经皮冠状动脉介入术(PCI)和行冠状动脉旁路移植术(CABG)的早期与远期安全性结果公布。文章7月8日在线发表于《循环心血管介入》(Circ Cardiovasc Interv)杂志。 该研究使用纽约州登记数据中并发糖尿病的行CABG或PCI治疗多血管疾病的患者数据,经过倾向性评分筛

JCEM:产前己烯雌酚暴露与心血管疾病风险有何关系?

这些数据表明,在产前DES暴露与CAD和MI相关,而与卒中无关,这种相关性似乎独立于已知的心血管疾病危险因素。

BMJ:新一代不可降解聚合物涂层药物洗脱支架综合性能更优

研究要点: 1.本项研究旨在比较生物可降解聚合物涂层药物涂层洗脱支架(DES)、裸金属支架和不可降解聚合物涂层DES的安全性与疗效。 2.生物可降解聚合物涂层DES的长期疗效优于紫杉醇洗脱支架和佐他莫斯洗脱支架,但不优于新一代不可降解聚合物涂层DES。综合而言,新一代不可降解聚合物涂层支架安全性和疗效综合性能最优。 第一代不可降解聚合物涂层药物洗脱支架(D